Immunogenic composition
First Claim
1. An immunogenic composition comprising a Haemophilus influenzae type b (Hib) saccharide conjugated to Tetanus Toxoid (TT), Neisseria meningitidis (N. meningitidis) serogroup C capsular saccharide (MenC) conjugated to TT, and N. meningitidis serogroup Y capsular saccharide (MenY) conjugated to TT, each saccharide having a dose, wherein the saccharide dose of the Hib saccharide conjugate is lower than the mean saccharide dose of the MenC saccharide conjugate and MenY saccharide conjugate.
1 Assignment
0 Petitions
Accused Products
Abstract
An immunogenic composition comprising a Hib saccharide conjugate and at least two further bacterial saccharide conjugates is provided, wherein the Hib conjugate is present in a lower saccharide dose than the mean saccharide dose of all the at least two further bacterial saccharide conjugates.
55 Citations
23 Claims
- 1. An immunogenic composition comprising a Haemophilus influenzae type b (Hib) saccharide conjugated to Tetanus Toxoid (TT), Neisseria meningitidis (N. meningitidis) serogroup C capsular saccharide (MenC) conjugated to TT, and N. meningitidis serogroup Y capsular saccharide (MenY) conjugated to TT, each saccharide having a dose, wherein the saccharide dose of the Hib saccharide conjugate is lower than the mean saccharide dose of the MenC saccharide conjugate and MenY saccharide conjugate.
-
17. An immunogenic composition comprising
(i) a Haemophilus influenzae type b (Hib) saccharide conjugated to a tetanus toxoid carrier protein, (ii) a N. meningitidis serogroup C capsular saccharide (MenC) conjugated to a tetanus toxoid carrier protein, and (iii) a N. meningitidis serogroup Y capsular saccharide (MenY) conjugated to a tetanus toxoid carrier protein, each saccharide having a dose, wherein the saccharide dose of the Hib saccharide conjugate is lower than the mean saccharide dose of the MenC and MenY saccharide conjugates, wherein the saccharide dose of the Hib saccharide conjugate is between 2 and 3 μ - g of saccharide and the saccharide dose of each of the MenC saccharide and MenY saccharide conjugates is between 4 and 7 μ
g of saccharide, andwherein the MenC saccharide has a molecular weight of above 50 kDa and the MenY saccharide has a molecular weight of above 50 kDa.
- g of saccharide and the saccharide dose of each of the MenC saccharide and MenY saccharide conjugates is between 4 and 7 μ
-
18. An immunogenic composition comprising
(i) a Haemophilus influenzae type b (Hib) saccharide conjugated to a tetanus toxoid carrier protein, (ii) a N. meningitidis serogroup C capsular saccharide (MenC) conjugated to a tetanus toxoid carrier protein, and (iii) a N. meningitidis serogroup Y capsular saccharide (MenY) conjugated to a tetanus toxoid carrier protein, each saccharide having a dose, wherein the saccharide dose of the Hib saccharide conjugate is lower than the mean saccharide dose of the MenC and MenY saccharide conjugates, wherein the saccharide dose of the Hib saccharide conjugate is between 0.1 and 9 μ - g of saccharide and the saccharide dose of each of the MenC saccharide and MenY saccharide conjugates is between 2 and 20 μ
g of saccharide, andwherein the MenC saccharide has a molecular weight of above 50 kDa and the MenY saccharide has a molecular weight of above 50 kDa.
- g of saccharide and the saccharide dose of each of the MenC saccharide and MenY saccharide conjugates is between 2 and 20 μ
-
19. An immunogenic composition comprising
(i) a Haemophilus influenzae type b (Hib) saccharide conjugated to a tetanus toxoid carrier protein, (ii) a N. meningitidis serogroup C capsular saccharide (MenC) conjugated to a tetanus toxoid carrier protein, and (iii) a N. meningitidis serogroup Y capsular saccharide (MenY) conjugated to a tetanus toxoid carrier protein, each saccharide having a dose, wherein the saccharide dose of the Hib saccharide conjugate is lower than the mean saccharide dose of the MenC and MenY saccharide conjugates, wherein the saccharide dose of the Hib saccharide conjugate is between 2 and 3 μ - g of saccharide and the saccharide dose of each of the MenC saccharide and MenY saccharide conjugates is between 4 and 7 μ
g of saccharide, andwherein the MenC saccharide has a molecular weight of above 100 kDa and the MenY saccharide has a molecular weight of above 100 kDa.
- g of saccharide and the saccharide dose of each of the MenC saccharide and MenY saccharide conjugates is between 4 and 7 μ
-
20. An immunogenic composition comprising
(i) a Haemophilus influenzae type b (Hib) saccharide conjugated to a tetanus toxoid carrier protein, (ii) a N. meningitidis serogroup C capsular saccharide (MenC) conjugated to a tetanus toxoid carrier protein, and (iii) a N. meningitidis serogroup Y capsular saccharide (MenY) conjugated to a tetanus toxoid carrier protein, each conjugated saccharide having a dose, wherein the saccharide dose of the Hib saccharide conjugate is lower than the mean saccharide dose of the MenC and MenY saccharide conjugates, wherein the saccharide dose of the Hib saccharide conjugate is between 0.1 and 9 μ - g of saccharide and the saccharide dose of each of the MenC saccharide and MenY saccharide conjugates is between 2 and 20 μ
g of saccharide, andwherein the MenC saccharide has a molecular weight of above 100 kDa and the MenY saccharide has a molecular weight of above 100 kDa.
- g of saccharide and the saccharide dose of each of the MenC saccharide and MenY saccharide conjugates is between 2 and 20 μ
-
21. A composition comprising:
-
(a) an immunogenic composition consisting of; (i) approximately 2.5 ug of Haemophilus influenzae type b (Hib) polyribosyl phosphate (PRP) capsular saccharide, said Hib PRP capsular saccharide conjugated to Tetanus Toxoid (TT), (ii) approximately 5.0 ug of N. meningitidis serogroup C (MenC) capsular saccharide conjugated to TT, and (iii) approximately 5.0 ug of N. meningitidis serogroup Y (MenY) capsular saccharide (MenY) conjugated to a TT carrier protein, 5 ug saccharide dose, and (b) a pharmaceutically acceptable excipient, where said composition does not comprise aluminium salt, and does not comprise any bacterial saccharides other than those of the immunogenic composition of (a).
-
-
22. A lyophilized composition comprising:
-
(a) an immunogenic composition consisting of; (i) approximately 2.5 ug of Haemophilus influenzae type b (Hib) polyribosyl phosphate (PRP) capsular saccharide, said Hib PRP capsular saccharide conjugated to Tetanus Toxoid (TT), (ii) approximately 5.0 ug of N. meningitidis serogroup C (MenC) capsular saccharide conjugated to TT, and (iii) approximately 5.0 ug of N. meningitidis serogroup Y (MenY) capsular saccharide (MenY) conjugated to a TT carrier protein, 5 ug saccharide dose; and (b) a stabilizing agent. - View Dependent Claims (23)
-
Specification